Page 1

August 19 , 2021 CollPlant Pioneering Regenerative Medicine CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results Co - Develop Agreement with 3D Systems Highlights Expanding Commercial Collaborations REHOVOT , Israel , Aug. 19 , 2021 / PRNewswire / -- CollPlant ( Nasdaq : CLGN ) , a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing , today announced financial results for the second quarter ended June 30 , 2021 and provided an update on the Company's business developments . " We are very excited with the momentum we are seeing in our efforts to leverage our plant- based human recombinant collagen platform and R & D capabilities to create products and collaborations that expand our addressable markets in medical aesthetics and 3D bioprinting , " said Yehiel Tal , CollPlant's Chief Executive Officer . " The year started strong with our AbbVie deal and that energy has continued with our recent co - development agreement with 3D Systems , an industry leader , for a 3D regenerative soft tissue matrix for breast reconstruction . This new agreement exemplifies the wide - ranging opportunities available for our rhCollagen - based products that can be used alone or in conjunction with other biomaterials in various fields including tissue engineering , regenerative medicine , 3D bioprinting , tissue and disease modeling , rapid drug screening , cell culture , and many other life sciences applications . " Recent Corporate Highlights • In June , CollPlant announced that it had entered into a strategic co - development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant . The soft tissue matrix is intended to support the lower portion of the breast while expanding the implant pocket and providing increased coverage of the implant . Using 3D bioprinting , these matrices can be designed to match the patient's anatomy to support the breast implant . • Continued to advance the ongoing partnership with Allergan Aesthetics , an AbbVie company , for the development and commercialization of dermal and soft tissue fillers for the medical aesthetics market . CollPlant entered into an agreement with AbbVie in February 2021 . • In June , CollPlant's ordinary shares were up - listed to Nasdaq Global MarketⓇ , together with transition from trading of ADS to trading of ordinary shares . • In a separate press release distributed today , CollPlant announced that Alisa Lask , a